PDE5A and pulmonary arterial hypertension: Similarly, in real-world data involving newly diagnosed USA patients with PAH, nearly 94% of patients commenced treatment with monotherapy and the most common treatment preference were PDE-5 inhibitors (70.0% of patients) [21].